

ENANTIOSPECIFIC SYNTHESIS OF THE IMMUNOPOTENTIATORS  
erythro-9 (2-HYDROXY-3-NONYL) HYPOXANTHINES AND THE threo-DIASTEREOMERS.

M. BESSODES<sup>\*†</sup>, E. ABUSHANAB<sup>††</sup> and K. ANTONAKIS  
Institut de Recherches Scientifiques sur le Cancer  
BP 8, 94802 VILLEJUIF CEDEX France

Summary : The title compounds were prepared enantiospecifically by kinetic resolution of (+/-) 1-nonene-3ol via Sharpless oxidation. The products 1,2R-epoxy-nonane-3S-ol and 1-nonene-3R-ol were efficiently converted to all four stereoisomers of 2-hydroxy-3-nonylamine, which were subsequently incorporated into the target hypoxanthines to evaluate their immunopotentiating activity.

(+/-) Erythro-9(2-hydroxy-3-nonyl) hypoxanthine (1, NPT 15392) has been reported to have immunopotentiating activity<sup>1</sup>. This compound is structurally related to the adenine analog 2 (EHNA), which is a potent inhibitor of adenosine deaminase<sup>2</sup>, and has antiviral activity in vitro<sup>3</sup>. It was recently shown<sup>4,5</sup> that chirality in the nonyl chain of EHNA played a role in determining binding to the enzyme, a property not observed in the antiviral evaluation of these compounds<sup>6</sup>. The structural similarities of 1 and 2, prompted us to synthesize the enantiomers and diastereomers of 1 to study the effect of chirality on the immunopotentiating activity.



We recently described the synthesis of 2S-hydroxy-3R-nonylamine starting from natural chiral synthons<sup>7</sup>. We report here the enantiospecific synthesis of the four stereoisomers of 2-hydroxy-3-nonylamine starting from non chiral substrates, and their conversion to the title compounds.

<sup>†</sup> Chargé de Recherche, INSERM

<sup>††</sup> On sabbatical leave from university of Rhode Island (USA), contrat INSERM

Retrosynthetic analysis led us to (+/-) 1-nonene-3-ol 3 as the starting material which is easily obtained from heptaldehyde and vinyl magnesium bromide. Oxidation of 3 using the Sharpless method<sup>8</sup>, ((+) DIPT, Ti(OiPr)<sub>4</sub>, anhydrous TBHP, -20°, 18 h) furnished a mixture of 3a and 4, separation of these compounds was accomplished by fractional vacuum distillation<sup>9</sup> to give pure 3a (bp 48°, 0.03 mm,  $[\alpha]_D = -13.4^\circ$ ,  $c = 1.12$  EtOH) and 4 (bp. 54°, 0.03 mm,  $[\alpha]_D = -4^\circ$ ,  $c = 1.24$  EtOH, 84 %<sup>10</sup>).

Protection of the hydroxyl group in 4 as the tetrahydropyranyl ether (DHP, TsOH 1 %, CH<sub>2</sub>Cl<sub>2</sub>, 30 mn) gave 5 which was regioselectively reduced (LAH, ether, 0°, 30 mn) to give alcohol 6 in 90 % overall yield from 4.


Benzoylation of 6 followed by acid hydrolysis led to the semi protected diol 8 (80 % overall). The azido derivative 9 was obtained by the modified Mitsunobu reaction<sup>11</sup> (Ph<sub>3</sub>P, DEAD, HN<sub>3</sub>, benzene, 2h, 20°) and was purified by flash chromatography (hexane, EtOAc 5 %, quantitative). Base hydrolysis of 9 followed by catalytic reduction over palladium (10 % on carbon, EtOH), afforded the threo 2R, 3R-hydroxyamine 11a ( $[\alpha]_D = +17^\circ$ ,  $c = 1.2$  EtOH).

The erythro 2S, 3R diastereomer 11b was obtained by a modification in the sequence of reaction just described. Thus catalytic reduction of the azido benzoate 9 gave after in situ transbenzoylation, benzamide 12 (mp. 106°).

Inversion of configuration at C-2 was accomplished through oxazoline 13a which was subsequently hydrolysed to 11b ( $[\alpha]_D = +11.8^\circ$ ,  $c = 0.93$ , EtOH).


Although the described sequence gave the chiral amines in very good yields, the number of steps required prompted us to search for a more efficient synthetic route. Thus treatment of epoxide 4 in the conditions described earlier<sup>11</sup>, gave quantitatively the azido epoxide 14 ( $[\alpha]_D = -19.6^\circ$ ,  $c = 1.25$  EtOH). Simultaneous LAH reduction of the two functionalities gave amine 11a, from which diastereomer 11b was obtained through oxazoline 13b<sup>12</sup>.

Similarly epoxidation of 3a using (-)DIPT and introduction of the azide function gave 15 ( $[\alpha]_D = +20.9^\circ$ ,  $c = 1.27$  EtOH); subsequent reduction gave the amine 11c ( $[\alpha]_D = -15.8^\circ$ ,  $c = 1.17$  EtOH), from which diastereomer 11d was obtained ( $[\alpha]_D = -14.5^\circ$ ,  $c = 1.2$  EtOH)<sup>13</sup>. Having completed the synthesis of the amines, their incorporation into the hypoxanthine nucleus followed published procedures<sup>14</sup>. Successive condensation of each amine with 5-amino-2,6-dichloropyrimidine and triethyl orthoformate furnished the corresponding chloropurines which were hydrolyzed to the title compounds 1a-d<sup>15</sup>:



	$[\alpha]_D, \text{EtOH}$	mp°
<u>1a</u> : 2R, 3R	+ 38.5°	176°
<u>1b</u> : 2S, 3S	- 32°	174°
<u>1c</u> : 2S, 3R	+ 30.4°	204°
<u>1d</u> : 2R, 3S	- 29.2°	193°

The potential synthetic utility of epoxy azides 14 and 15 as well as the synthesis of analogs of NPT 15392 are currently under investigation.



TABLE

 $^1\text{H}$  ( $\text{CCl}_4$ ) and  $^{13}\text{C}$  ( $\text{CDCl}_3$ ) nmr chemical shifts (in ppm from TMS)

Compound	H1	H2	H3	C1	C2	C3
<u>4</u>	2.8	3	3.8	43.7	54.8	68.9
<u>3a</u>	5.1	5.9	4.1	114.4	141.5	73.2
<u>7</u>	1	5-5.4	3.6-3.8	22.6	78.7-77.9	
<u>9</u>	1	5.1	3.1	17.4	72.9	65.5
<u>11a</u>	1	3.5	2.4	20.3	70.2	57.5
<u>12</u>	1		3.8	20.4	68.5	54.9
<u>13a</u>	1.3	4.8	4.1	15.7	76	71
<u>14</u>		2.8-3.2		44.9	54.4	64.1

## Acknowledgments

The authors thank Dr. K.B. Sharpless for a gift of the diisopropyl tartrates and for helpful discussion. We also wish to thank Dr. M.T. Chenon for the  $^{13}\text{C}$  nmr spectra.

## References :

- 1 - V.J. Merluzzi, M.M. Walker, N. Williams, B. Susskind, J.W. Hadden and R.B. Faanes, *Int. J. Immunopharmacol.*, 4, 219, (1982).
- 2 - R.P. Agarwal, T. Spector and R.E. Parks, Jr., *Biochem. Pharmacol.*, 26, 359, (1977).
- 3 - T.W. North and S.S. Cohen, *Proc. Nat. Acad. Sci.*, 75, 4684, (1978).
- 4 - M. Bessodes, G. Bastian, E. Abushanab, R.P. Panzica and S.F. Berman, E.J. Marcaccio, Jr., S.F. Chen, J.D. Stoeckler, R.E. Parks, Jr., *Biochem. Pharmacol.*, 31, 879, (1982).
- 5 - D.C. Baker, J.C. Harvey, L.D. Hawkins and J. Murphy, *Biochem. Pharmacol.* 30, 1159, (1981).
- 6 - T.W. North, L. O'Connor, R.P. Panzica and E. Abushanab, *Biochem. Pharmacol.* 32, 3541, (1983).
- 7 - E. Abushanab, M. Bessodes and K. Antonakis, *Tetrahedron Lett.*, 25, 3841, (1984).
- 8 - T. Katzuki and K.B. Sharpless, *J. Am. Chem. Soc.*, 102, 5974, (1980).  
V.S. Martin, S.S. Woodard, T. Katzuki, Y. Yamada, M. Ikeda and K.B. Sharpless, *J. Am. Chem. Soc.*, 103, 6237, (1981).
- 9 - The decomposition of excess tBHP was accomplished using excess  $\text{NaBH}_4$ . This reagent formed a borate ester with DIPT and prevented its distillation thus allowing the separation of 3a and 4. The use of other reducing agents was less satisfactory.
- 10 - This yield was calculated considering the oxidation of only one enantiomer of racemic 1.
- 11 - H. Loibner and E. Zbiral, *Helv. Chim. acta*, 59, 2100, (1976).
- 12 - The optical rotations were in agreement with values obtained earlier : M. Bessodes, G. Bastian, R.P. Panzica and E. Abushanab, unpublished results.
- 13 - Presented at the V international conference on organic synthesis (ICOS-5, Freiburg I. Br., 1984), Abstr. N° T42.
- 14 - H.J. Shaeffer and C.F. Schwender, *J. Med. Chem.*, 17, 6, (1974).
- 15 - Satisfactory elemental analysis have been obtained on all key compounds.

(Received in France 28 September 1984)